Pfizer’s Paxlovid, the newly approved anti-viral tablet that reduces the risk of COVID-19 hospitalizations or death by almost 90%

On December 22nd 2021, the FDA (U.S. Food and Drug Administration) issued an emergency authorization for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use), for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years… Read More